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Abstract: Lactoperoxidase (LPO) present in saliva are an important element of the nonspecific
immune response involved in maintaining oral health. The main role of this enzyme is to oxidize
salivary thiocyanate ions (SCN−) in the presence of hydrogen peroxide (H2O2) to products that
exhibit antimicrobial activity. LPO derived from bovine milk has found an application in food,
cosmetics, and medical industries due to its structural and functional similarity to the human enzyme.
Oral hygiene products enriched with the LPO system constitute an alternative to the classic fluoride
caries prophylaxis. This review describes the physiological role of human salivary lactoperoxidase
and compares the results of clinical trials and in vitro studies of LPO alone and complex dentifrices
enriched with bovine LPO. The role of reactivators and inhibitors of LPO is discussed together with
the possibility of using nanoparticles to increase the stabilization and activity of this enzyme.
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1. Introduction
Lactoperoxidase (LPO, EC.1.11.1.7) is an enzyme secreted, inter alia, to saliva, milk, and other body
fluids, and participates in an unspecific humoral immune response directed against bacteria, fungi,
and viruses within mucous membranes [1]. LPO forms the LPO system together with thiocyanate ions
or iodides or bromides and hydrogen peroxide. The mechanism of action of this system is based on
oxidation of thiocyanate ions (also iodides and bromides) to hypothiocyanite ions (hypoiodides and
hypobromides) with the use of hydrogen peroxide. Hypothiocyanite ions oxidize the thiol groups of
amino acid residues of microbial proteins, leading to their impaired function and, thus, inhibition of
the cell division or death of the microorganism [2].
In the context of the oral cavity, the LPO system is one of the main mechanisms of anti-caries
defense [3], moreover, regulating the composition of microflora and preventing the growth of
pathogenic microorganisms present in periodontitis [4]. The physiological properties of the enzyme
have been used in the prevention of these diseases through the creation of oral hygiene preparations
enriched with the LPO system. The industrial source of this enzyme is bovine milk, whose methods
of purification have been well defined, resulting in an enzyme characterized by large structural and
functional similarity to human lactoperoxidase [5].
The aim of this review was to present the latest knowledge about the physiological role of human
salivary lactoperoxidase. In addition, the paper presents the results of clinical trials of dentifrices
enriched with LPO and in vitro tests of the LPO system itself. The role of reactivators and inhibitors of
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LPO, which have been intensively investigated in recent years, has also been described together with
the use of nanoparticles to stabilize and increase the enzyme activity.
2. Genetics, Structure and Physicochemical Properties of Lactoperoxidase
2.1. Genetics
Lactoperoxidase together with myeloperoxidase (MPO), thyroid peroxidase (TPO), and eosinophil
peroxidase (EPO), belong to the family of animal heme peroxidases, i.e., one of the four superfamilies
of heme peroxidases [6]. Genes encoding human LPO, MPO, and EPO are found on chromosome
17 and form a cluster covering a region of 90,000 base pairs [7]. Their proximity of location and the
same number of exons (12) may suggest that they evolved from one ancestral gene which has been
duplicated [8]. In cattle, the gene of LPO is located on chromosome 19 and has 18 exons [9].
Comparison of cDNA sequences of cloned human milk LPO [10] with a sequence of cloned
salivary peroxidase (SPO) [11] and other sequences of human LPO [7,12], showed sequence identity,
which means that lactoperoxidase contained in saliva and other body fluids is a product of the same
gene found on chromosome 17q22 [7].
In humans, there are three possible transcript variants created as a result of the alternative splicing
of LPO mRNA, i.e., a major variant 1 (V1), including the complete coding sequence, variant 2 (V2),
lacking exon 3, and variant 3 (V3), lacking exon 3 and 4. This is associated with the termination of
translation after the secretory signal peptide in the case of V2, and a propeptide deletion in the case of
V3. It has been shown that both V1 (the most numerous one) and V3 have enzymatic activity, and the
activity of V3 is greater than that of V1 [13].
2.2. Structure and Physicochemical Properties
Lactoperoxidase (both human and bovine) is a single chain, monomeric glycopeptide of
approximate mass of 80,000 Da (human) or 78,000 Da (bovine) [5,14]. Each LPO molecule contains one
molecule of modified autocatalytic heme B in its active center [9,15],
Like in many peroxidases, the calcium atom associated with Asp227 plays an important role in
maintaining structure, thermal stability, and enzyme activity. Shin et al. showed that modification of
this protein leading to the loss of calcium binding capacity results in a complete loss of activity [16],
while Booth et al. described the consecutive precipitation of the enzyme by its subjecting to
guanidinium hydrochloride to release calcium [17].
The mRNA analysis showed that both human and bovine LPO is composed of 712 amino acid
residues and is characterized by 83% similarity, while protein analysis showed that human LPO
is composed of 632 amino acid residues (including 16 cysteine residues) and a bovine one of 612
(including 15 cysteine residues) [9,15,18]. The difference between the theoretical length of the chain
and the length of the analyzed protein results from the occurrence of post-translational modifications
consisting of the cleavage of the propeptide and the signal peptide [13]. Bovine LPO can undergo
N-glycosylation in five positions, while human LPO can undergo N-glycosylation in four [14]. During
the SDS-PAGE analysis of human LPO, one can identify several bands derived from this enzyme. This
fact can be explained by the presence of LPO with different degrees of glycosylation [16,19]; although
this phenomenon may also be related to the heterogeneity of the protein chain [10].
Differences in structure, physicochemical properties and chemical activity between human and
bovine lactoperoxidase are small (Table 1). Due to their high similarity and the lower price of bovine
LPO, scientific research often uses it, as its purification procedures have also been well described. For
industrial applications, the most commonly used enzyme is LPO from bovine milk [10].
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Table 1. Structure and physiochemical properties of human and bovine lactoperoxidase.
Characteristic Value Reference
Mass ~80 000 Da (hLPO);~78 000 Da (bLPO) [10,18]
Gene-containing chromosome 17 (hLPO);19 (bLPO) [7,20]
Number of amino acid residues 632 (hLPO);612 (bLPO) [18]
Number of glycosylation sites 5 (hLPO);4 (bLPO) [14]
Isoelectric point 9.6 [18]
Optimal conditions 50
◦C;
pH = 6 [5]
Stability of the secondary structure Start of degradation at 65
◦C;
Tm = 71.2 ◦C [15]
Stability of heme
Start of degradation at 70 ◦C;
Tm = 73 ◦C;
Degradation at pH < 4
[15]
3. Secretion in Physiological and Pathological Conditions
Lactoperoxidase is secreted to milk [16], tears [21], cervical mucus [22], mucus of the respiratory
tract [23], and saliva (by epithelial cells of the acinus in submandibular and parotid salivary
glands) [24,25]. In addition to epithelial lactoperoxidase, saliva contains myeloperoxidase derived
from azurophilic granules of polymorphonuclear leukocytes, whose concentration increases with the
appearance of dentition [26]. The increase in MPO concentration is associated with oral inflammation
and is characteristic of periodontitis [27,28]. Unlike myeloperoxidase, the secretion of epithelial LPO
is not dependent on the occurrence of inflammation. Infammation, however, does have an effect on
function of LPO. Intensification of oxidation processes increases the prodution of H2O2 which, in
turn, directs LPO into the peroxidation cycle which is inefficient in terms of formation of reactive
products [29].
After the secretion to saliva, part of salivary peroxidase undergoes irreversible adsorption on
the tooth enamel surface [30], dental plaque [31], and synthetic surfaces [32], which is reinforced by
its defensive properties against microbial colonization of these surfaces. In addition, the adsorption
process may contribute to an increase in the specific activity of the enzyme [33]. A strong modulating
effect on this phenomenon has been demonstrated by other salivary proteins, mainly mucins [34].
The concentration of salivary lactoperoxidase undergoes changes throughout life. Its secretion
is identified in neonates a few hours after delivery, while its concentration in this group shows high
inter- and intraindividual variability [35]. Salvolini et al. showed that the highest concentrations of LPO
in saliva are met in a group of healthy individuals aged 10–24, then its concentration decreases with
age [36]. Changes in the secretion of LPO due to the circadian cycle have also been identified, with the
highest concentration occurring around noon [37], which may be associated with increased physical
activity [38]. During exercise, it comes to the formation of superoxide anion radical in the mitochondria
of skeletal and cardiac muscles, which is then spontaneously or catalytically (with superoxide dismutase)
converted to H2O2. In addition, there is an increase in the activity of NAD(P)H oxidase and xanthine
oxidase also responsible for the formation of hydrogen peroxide [39]. It has been shown that in response
to the reactive oxygen species formed during exercise, it comes to an increase in the production of
salivary antioxidants, including LPO responsible for the decomposition of toxic H2O2 [40].
Salivary LPO concentration changes over the course of the menstrual cycle, and the peak of
secretion overtakes ovulation by a few days [41,42]. In addition, its elevated level is observed in the
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third trimester of pregnancy [43]. The reason for this increase is the estrogen sensitivity of the salivary
glands due to the expression of estrogen receptors β (ER β) on the acinar and ductal cells of salivary
glands [44,45].
Another factor that can affect the activity of LPO in saliva is smoking and alcohol consumption.
Goi et al. showed that peroxidase activity in smokers’ saliva is lower than in nonsmokers [46],
which may be the result of irreversible inactivation of LPO by hydrogen cyanide present in tobacco
smoke [47,48]. Waszkiewiecz et al. described significantly increased levels of salivary peroxidase in
people who drink alcohol, which is not the effect of thickening caused by decreased salivary flow, but
may be a response to an increased production of superoxide anion radical and hydrogen peroxide
by CYP2E1 (belonging to the cytochrome P450 family) responsible for the ethanol metabolism [49].
This cytochrome is induced at the level of transcription, translation and post-translational modifications
in people who consume ethanol on a long-term basis [50,51]. A different effect was observed among
patients with acute alcohol intoxication where LPO level was significantly lower at 36 and 108 h after
poisoning [52].
Xylitol, a polyol used in nonfluoride caries prophylaxis, besides depriving microorganisms
of energy in futile cycle of 5-xylitol phosphate formation followed by its dephosphorylation and
excretion [53], stimulates the secretion of LPO into the saliva [54] without affecting its adsorption
on enamel [55]. Numerous studies are conducted in search of a connection between the occurrence
of certain oral conditions and changes in the LPO synthesis. A decrease in its concentration has
been reported in periodontitis (28 juvenile patients; 46 subjects, 25–54 years) [37,56] in contrast to
patients with both type 1 diabetes and periodontitis (10 patients) who demonstrated an increase in
LPO activity which may be associated with co-occurring xerostomia and production of concentrated
saliva [57,58]. Other studies have shown no significant associations between the occurrence or severity
of periodontitis and LPO salivary concentration [59,60]. Bielawski et al. described an increase in LPO
salivary concentration in patients with caries (n = 27) compared to the healthy group (n = 8) [61], while
no significant differences between these groups were found in the studies conducted by Lamberts et
al. (29 patients, 29 controls) [62]. The search for the relationship between the concentration/activity
of LPO is also conducted among patients with oral lichen planus [45] or aphthous stomatitis [63].
Discrepancies in the results obtained by particular teams may result from too small homogeneity of the
examined groups, inadequate power of statistical tests and numerous physiological factors affecting
the release of LPO.
4. Industrial Sources of LPO and Methods of Its Purification
Milk is a body fluid most rich in lactoperoxidase. This enzyme has been identified in milk
in humans [35], cows [64], buffalos [65], goats [66], sheep [67], camels [68], and guinea pigs [69].
Figure 1 shows the activity of LPO in the milk of different species. Bovine milk is the most commonly
used source of LPO both for laboratory and in vivo use due to its high availability and high LPO
concentration of ~30 mg/L depending on the diet or time of the day or year [18]. Both pure LPO
preparations and other microbiologically reactive components such as lactoferrin or immunoglobulins
are used in the production of oral hygiene preparations [70,71]. There are methods that have been
developed for obtaining clean preparations of LPO and lactoferrin in one process [72].
LPO purification procedures on both industrial and laboratory scales cover many stages and
are time-consuming. Prior to the application of specific cleaning techniques, certain processes are
used to densify the material and eliminate the main undesirable substances. These processes include
fat centrifugation, removal of casein by adding rennet, removal of unnecessary major milk protein
fractions, and concentration by precipitation with ammonium sulfate [5,64].
The use of affinity chromatography allows to obtain very pure LPO preparations (e.g., purification
fold 3397, 7.6% yield, using IgG anti-LPO [16]), however this method is relatively expensive. Atasever
et al. developed a one-step method based on sulfonamide affinity chromatography characterized by
61.3% yield and purification fold of 409 [73].
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Methods based on ion exchange chromatography are preferred for a large-scale production but
have lower purification fold compared to affinity chromatography methods [74]. A method using
ion exchange resins (CM-cellulose) developed by Borzouee et al. obtained a LPO preparation with a
10.26% yield and purification fold of 59.13 [5]. Uguz et al. described a method using Amberlite CG
50 H+ ion exchange resin and double gel filtration using Sephadex G-50 and Sephadex G-100 that
obtained a LPO formulation with a 28% yield and purification fold of 11.5 [64].
The purity of the obtain d LPO preparation can be deter ned by direct measurement
of absorbance at 412 nm (reflecting LPO he concentration) and at 280 nm (reflecting protein
concentration) as well as their ratio (Rz coefficient). The closer Rz value to 0.95 (absorbance ratio at
412 nm and 280 nm of pure LPO), the lesser LPO preparation is contaminated with other proteins [75].
5. Substrates—Availability and Importance
5.1. Hydrogen Peroxide
Hydrogen peroxide concentration in saliva equals to 8–13 µM under physiological conditions [76],
and increases several fold in inflammatory diseases of the mouth [77]. Its production is ensured by
both oral microorganisms as well as by the cells and enzymatic systems of the host [18], while bacterial
production is sufficient to ensure the proper functioning of the salivary lactoperoxidase system.
Bacteria of Streptococcus genus, such as S. sanguinis, S. mutans, S. sobrinus, and S. mitis, belong
to the main microorganisms involved in production of H2O2 [78–80]. Microorganisms secrete it in
order to inhibit the growth of other microorganisms, regulate the biofilm formation, and facilitate the
exchange of genes between bacteria in biofilm [81].
Bacterial production of hydrogen peroxide is most strong under aerobic conditions at the access to
simple sugars and is the result of the action of enzymes such as NADH oxidase (EC.1.6.3.1) [80], lactic
acid oxidase (LAo, EC.1.1.3.2) (in the stationary phase) [82], L-amino acid oxidase (EC.1.4.3.2) [83], and
predominantly pyruvate oxidase (EC.1.2.3.3) (in the log phase) [84].
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The ability to produce hydrogen peroxide by human salivary gland cells was proven only in the
first years of the 21st century. It has been shown that it is synthesized as a result of the action of NADPH
oxidases (NOX 1–5 and DUOX2 dual oxidase) and superoxide dismutase (SOD, EC.1.15.1.1) [85,86].
The industrial sources of this substrate for dentifrices comprise such H2O2-generating enzyme
systems, as glucose oxidase (GOx EC.1.1.3.4), lactose oxidase [87], and xanthine oxidase (XO,
EC.1.17.3.2) [18,88].
5.2. Thiocyanates, Iodides, Bromides
Thiocyanate ions are the most important substrate for lactoperoxidase in terms of defensive
properties, and are present in all mammalian body fluids, including plasma, milk, saliva, tears,
respiratory epithelial fluid, and sweat [89–91]. The highest SCN− concentration is recorded in saliva
(0.3-3 mM), which is the result of active secretion of these ions [90,92–94].
These ions are released by the action of myrosinase on glucosinolates provided to the body
mainly with Brassica vegetables such as cabbage, brussels sprouts, broccoli, kale, kohlrabi, and Chinese
cabbage [95].
Thiocyanates migrate from plasma to epithelial gland cells through sodium/iodide symporters
(NIS), and then to glandular secretion through cystic fibrosis conductance regulator channels
(CFTR) [96,97], anoctamin-1 (ANO1, also called transmembrane member 16A, TMEM16A) belonging
to calcium-activated chloride channels (CaCC) [98] or pendrins [99].
Besides thiocyanates, iodides, and bromides are other substrates for salivary peroxidase, however
playing a less important role in microbial defense due to their low physiological concentration.
In contrast to SCN− whose industrial source is potassium thiocyanate [100,101], these substrates
are not used in industry as an additive to oral care products.
6. Chemical Mechanism of Action
The first stage in the cycle of lactoperoxidase activity is the transition from the native form to
Compound I by the two-electron oxidation in the presence of hydrogen peroxide (alternatively, organic
peroxides [102]), which is reduced to water [18].
The creation of Compound I can be represented by the reaction
LPO (native form) + H2O2 → LPO (Compound I) + H2O
6.1. Halogenation Cycle
LPO Compound I can enter the cycle of halogenation in the presence of two-electron donors such
as SCN−, I−, and Br−. It passes through a one-step two-electron reduction of Compound I to the native
form. (Pseudo)halides (I−, Br−, and SCN−), in turn, oxidize to hypo(pseudo)halides (OI−, OBr−,
and OSCN−) giving up two electrons [2,103]. SCN− is the most preferable ion for oxidizing under
physiological conditions, considering that its highest concentration is associated with high supply
with food, active secretion into the saliva and the highest value of the reaction rate constant [104,105].
In summary, the reaction of the halogenation cycle can be represented as follows:
LPO (Compound I) + X− → LPO (native form) + OX−
6.2. Peroxidation Cycle
The peroxidation cycle consists of a two-electron reduction to the native enzyme form with the
formation of a Compound II intermediate [2]. The literature describes a large number of substrates
(both endogenous and exogenous) involved in this cycle [65,106–108]. The second stage of reduction is
described as a step limiting the speed of lactoperoxidase system due to the relatively long recovery
time to the native form. It is a disadvantageous step from the point of view of antimicrobial activity,
because of competing with the halogenation cycle, where microbial-reactive products are produced [2].
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The reactions of the peroxidation cycle can be presented as follows
LPO (Compound I) + AH→ LPO (Compound II) + A•
LPO (Compound II) + AH→ LPO (native form) + A•
6.3. Inactive Forms
Enzymatically inactive LPO Compound III is formed in the case of a molar excess of H2O2 (which
may occur in the course of oral inflammatory diseases) and in the absence of single-electron donors
or in reaction with hydroperoxyl radical [109]. Compound III may to a certain point undergo partial
reactivation to Compound II [109,110]; however, it comes to an irreversible inactivation after a longer
period of high H2O2 concentrations, through damage to heme and the release of iron.From an industrial
point of view, selecting the ratio of lactoperoxidase and H2O2-generating system concentrations is an
important aspect of designing preparations with LPO system in order to minimize the risk of inactive
lactoperoxidase. It may also be important to use additions of LPO reactivators to prevent the formation
of inactive forms and the entry of LPO into the peroxidation cycle at elevated H2O2 concentration in
oral pathologies [29].
6.4. Reactivators
In recent years, a large number of substances have been described to react with LPO Compound
II, reducing it to the native form. This action ensures rapid regeneration of the inactive (in term of
reactive products formation) Compound II and prevents the formation of Compound III and constant
enzyme inactivation.
The most effective reactivators are those substances that show a high value of constant of reaction
with Compound II, thus acting only as reactivators of this form [111]. At present, while there are
neither in vitro studies in microbiological models nor clinical trials, only studies of the molecular
mechanism of interaction of these substances with LPO; one can assume that this mechanism may
constitute a new fixture point in the prevention of caries [112].
Reactivators include many substances of natural origin belonging to flavonoids [111],
polyphenols [29], tannins [77], and cinnamic acid derivatives [112]; moreover, there are ongoing
studies on the use of plant extracts containing more than one substance with such an effect [113,114].
In addition to the direct bactericidal action, Flemmig et al. showed the reactivating properties of some
components of the Olea europaea extract on LPO Compound II [113]. Similarly, Gau et al. demonstrated
the reactivating properties of tannins and their derivatives, which also exhibit direct bactericidal
and anti-inflammatory effects [77]. During the investigation of the reactivation outflow of Leonurus
cardiaca extracts performed by Flemmig et al., the team drew attention to the need of usage of selective
extraction processes to enrich extracts with selected groups of active compounds and to prevent the
extraction of inhibitors [113].
6.5. Inhibitors
The biocidal activity of LPO can be inhibited by numerous substances acting through three
main mechanisms. The first of them is the pre-enzymatic mechanism consisting in competing
for access to substrates. This group of inhibitors may include physiological salivary components
such as myeloperoxidase (whose concentration increases in periodontitis [115]) and catalase [116]
competing for hydrogen peroxide with LPO, or uric acid present in saliva at high concentration and
competing with SCN− ions [117]. The second group of inhibitors are substances interacting with
the enzyme molecule, e.g., cyanides, azides, or thiourea [2]. The third postenzymatic mechanism of
inhibition is associated with the reduction of reactive lactoperoxidase products. This group includes
compounds containing thiol groups, such as glutathione present in saliva (whose concentration
increases in caries [118]), which may lead to the weakening of the LPO system. This group also
includes NADH-OSCN oxidoreductase, which is responsible for the OSCN− breakdown to SCN− [80].
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The inhibitory effect on LPO is also exerted by commonly used drugs, e.g., some indazoles [119],
carbidopa [120], salicylic acid and some other phenolic acids [121], propofol [122], some antibiotics,
and some corticosteroids [123].
7. Biological Role of the LPO System
7.1. Mechanism of Biocidal Activity
The key products of the lactoperoxidase system are hypothiocyanite ions (OSCN−) and
hypothiocyanous acid (HOSCN) formed during the oxidation of thiocyanates [124,125]. Both
products are in a dynamic equilibrium state, transforming into one another. The ratio of dissociated
form (OSCN−) to undissociated one (HOSCN) depends on the pH of the environment [126].
Hypothiocyanites have a strong selective oxidizing activity on the thiol moieties of key enzymes
in the course of glycolysis in microorganism [127,128]. The mechanism of inactivation: a transient
product (R-S-SCN) is formed as a result of the thiol group (R-SH) oxidation, which then breaks down to
release a hydroxythiol moiety (R-S-OH); thiocyanate ions that can be reoxidized and undergo further
reactions with thiol groups [128]. This is summarized by the following reactions.
R-SH + OSCN− → R-S-SCN + OH−
R-S-SCN + H2O→ R-S-OH + SCN− + H+
Nevertheless, the inhibitory effect of OSCN− ions on the growth of microorganisms may be
reversible if these ions are removed from the environment and there is a correspondingly high
concentration of reducing agents as glutathione or NAD(P)H in the cell [128]. The presence of
intracellular NADH: hypothiocyanite oxidoreductase in commensal Streptococcus sanguinis effectively
protects them against undesirable inhibition of growth [129]. Only the prolonged duration of
HOSCN activity on the cells has the effect of irreversible inhibition due to further modification
of the intermediate R-S-OH and R-S-SCN products [128].
The concentration of iodides in saliva is below 1 µM, hence their physiological oxidation by LPO
is marginal as compared to thiocyanates. HOI, IO−, as well as I2, I3−, and I2OH− are the products of
the reaction between I− and salivary peroxidase Compound I [130,131]. These products have a broader
range of activity than hypothiocyanites, as they oxidize NAD(P)H and thioether groups in addition to
the thiol moieties of proteins [2,132]. In addition to the bacteriostatic effect of hypothiocyanites, the
products of iodide oxidation show bactericidal and fungicidal activity. Vanden Abbeele et al. observed
a positive effect of mouth rinse on the reduction of dental plaque in in vivo studies using a mouthwash
containing OI− [133]. Comparing the efficacy of antifungal activity on Candida blastophores, the
survival rate in the LPO system containing thiocyanate was 56–88%, whereas it was 0–4% in the system
where iodides were applied [134]. Ahariz et al. observed greater effectiveness of the iodide system
in limiting the growth of C. albicans blastoconidial biofilms on titanium surfaces in comparison to
the LPO–H2O2–SCN− system [135]. OI− ions have a broad biocidal activity range, including fungi
and Gram-negative and Gram-positive bacteria, and show synergy with SCN− ions in LPO system
(stronger activity than SCN− alone) [136]. Schlorke et al. presented another possible product of the
LPO system—cyanogen iodide (ICN)—which is formed in the presence of both SCN− and I−. The
strong toxic effects of this product have been described, however the exact mechanism of its action
on microorganisms is not known. Although physiological formation of ICN does not occur, it seems
that such selection of the SCN− and I− ratio in dentifrices generates significant amounts of cyanogen
iodide and may be important in increasing their antimicrobial efficacy [137].
7.2. The Effect of the LPO System on Dental Plaque
In both caries and periodontitis, the formation of plaque or biofilm is a key element in
the pathomechanism of these diseases. In the course of caries, the biofilm has supragingival
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localization [138], but is subgingival in periodontitis [139]. The LPO properties that inhibit the
formation of biofilm at each stage of its formation have been demonstrated in literature. Due to the
ability of adsorption on salivary pellicle [33], the effectiveness of the LPO system has been proved in
preventing adhesion of precursor cariogenic microorganisms [140]. Similar studies have also been
conducted on mature biofilms for both single- and multispecies. Cawley et al. demonstrated that the
LPO system together with lactoferrin, lysozyme, and bovine milk immunoglobulins have the ability to
inhibit the formation of single-species S. mutans biofilm, whereas, in the case of multispecies biofilms
(which more accurately represents biofilms occurring in vivo), its application resulted in the loss of
microbial viability without the decrease in biofilm mass [141]. This fact can be explained by the ability
of the LPO system to kill microorganisms, but the inability to inactivate glucosyltransferases, i.e.,
extracellular bacterial enzymes responsible for the synthesis of glucans building a biofilm matrix [142].
7.3. Inhibition of Organic Acids Production
The local effect of organic acids produced by microorganisms as a result of carbohydrate
metabolism is the direct factor causing the demineralization of the tooth surface in the course of
caries [138]. Tenovuo et al. demonstrated that a dental plaque treated with the LPO system ex vivo
produces less acids than the plaque in the absence of this system [42]. In addition, the production
of acids is inversely proportional to the concentration of hypothiocyanates [143]. The reason for
this may be the ability of the LPO system to inhibit glycolysis enzymes (one of the pathways
responsible for acid production) such as hexokinase, 3-phosphoglyceraldehyde dehydrogenase,
aldolase, and glucose-6-phosphate dehydrogenase [128,144–146]. In addition, the LPO system impairs
glucose transport, which is probably caused by damage to the integrity of the cell membrane GLUT
transporters [147–149].
With decreasing pH, the concentration of the dissociated form decreases and the concentration
of undissociated forms of the halogenation cycle increases. The undissociated form is characterized
by stronger biocidal properties due to the easier penetration of hydrophobic cell membranes [126].
This elevates the antibacterial effectiveness in caries, when the pH of plaque microenvironment is
reduced (pH< 6) [150] against saliva (pH = 6.7–7.3) due to the production of organic acids (such as
lactic and acetic acid) by bacteria (S. mutans and L. acidophilus) [124,151,152].
7.4. Defense against Oxidative Stress
As already mentioned, the production of H2O2 takes place in the oral cavity both by
microorganisms and host cells. This compound is toxic against microorganisms and host cells such as
epithelial cells or mucosal fibroblasts [1]. Its micromolar concentrations may induce aldehydic DNA
lesions in the Fenton reaction pathway of mitochondrial and nuclear DNA [153]. Moreover, H2O2
causes lipid peroxidation of the cell membrane [146].
The toxicity of hydrogen peroxide is much higher than that of hypothiocyanates formed in
halogenation cycle due to the entry of H2O2 into the Fenton reaction and the formation of a toxic
hydroxyl radical [154]. H2O2 is decomposed not only in the LPO halogenation cycle, but also in
reaction with the hypothiocyanate to produce water, molecular oxygen, and thiocyanate [146].
H2O2 + OSCN− → H2O2 + O2 + SCN−
Therefore, protection of the host against ROS damage is another important function of LPO.
7.5. Effect on Carcinogens
Saliva is the first fluid that comes into contact with food and participates in its digestion in
addition to its function of carcinogens inactivation. Along with food, numerous carcinogens are
supplied to the organism, e.g., benzo(a)pyrene, aflatoxins, or pyrolisates of amino acids and proteins.
Nishioka et al. demonstrated that human saliva has the ability to inactivate the mutagenicity of
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these compounds [155]. One of the proposed mechanisms of their inactivation is oxidation in the
peroxidation cycle of lactoperoxidase [156].
On the other hand, the ability of LPO to activate certain carcinogens was also identified. There are
studies proving that LPO increases the ability to bind DNA while entering the peroxidase cycle with
arylamine carcinogens, which is the cause of the mutagenic activity of these compounds [157,158].
8. Clinical Application
8.1. Review of Clinical Trials and In vitro Tests
Commercially available dentifrices containing lactoperoxidase have been subjected to clinical trials
involving participants from various age groups with various clinical conditions, e.g., malodor [159,160],
xerostomia [161], caries [3], and chronic periodontitis [4], as well as healthy subjects [101,141,162–164].
The usefulness of LPO preparation was also determined during pilot studies in neonates under
mechanical ventilation in order to avoid ventilator-associated pneumonia (VAP) [165]. The summary
of clinical trials is provided in the first part of Table 2.
In vitro studies on the effect of lactoperoxidase on oral microorganisms are being constantly
published and document its effects against Streptococcus mutans in caries, when used separately [142,
166–170] or in combination with lactoferrin, lysozyme, or immunoglobulins [140,141,171–174].
The ability of S. mutans to create biofilms have been taken into account together with the activity
of glucosyltransferases responsible for the synthesis of exopolysaccharides that build the biofilm
matrix [142,166,168]. It has been observed that the mouth rinse foam effectively reduces the retention of
biofilms produced by salivary as well as nonpathogenic bacteria of the oral cavity [171]. In addition to
S. mutans, studies also concentrate on other oral streptococci [141,167,170], species associated with the
occurrence of periodontal disease [141,169,170] and C. albicans fungi [167,173]. The summary of in vitro
tests is presented in the second part of Table 2.
8.1.1. Caries Prevention
The studies on the anti-caries effect of the LPO system show that it is most often assessed based on
the impact on S. mutans species, which is an important element of caries development due to the ability
of biofilm formation and fermentation of dietary carbohydrates. The acquisition of these pathogens at
an early age is a key element in the development of early childhood caries (ECC) in children.
Short-term studies involving children affected by ECC showed that the use of fluoride-free,
fluoride and enzymatic paste caused a decrease in salivary S. mutans within seven days. The decrease
observed in the group using the enzymatic paste was the most significant, in addition to a decrease in
L. acidophilus amount [3]. A similar effect was observed by Jyoti et al. during a 4-week study using a
different enzyme paste in children with ECC where the content of salivary S. mutans and Lactibacillus
also significantly decreased, which was associated with an increase in the concentration of thiocyanates
in saliva during the paste use [175]. Lenander-Lumicari et al. did not observe any antibacterial effect
on salivary S. mutans and Lactobacillus in a 4-week study with the use of LPO paste in adults [176].
The short-term effect of using the paste with the LPO system is based on a significant increase in
the saliva content of active proteins and compounds. Cawley at al. compared the levels of H2O2 and
lysozyme found in saliva directly after brushing, showing 64% and 92% higher levels, compared to the
control paste, respectively [141]. The same team had also described an increase in hypothiocyanates
(above 100 µM) generated by the LPO system in vitro in the saliva of volunteers after adding to it
the test paste. Lenander-Lumicari et al. observed an elevated HOSCN/OSCN− level (even to about
300 µM) in saliva directly after 1 min of brushing (maintained up to 20 min) [176].
Lactoperoxidase affects the enzymes involved in the synthesis of EPS that build a biofilm matrix, in
addition to activity against glycolytic enzymes. Korpela et al. showed that lactoperoxidase showed an
inhibitory effect on all glucosyltransferases in a certain concentration range in the absence of substrates.
The activity of adsorbed D and C transferases in the LPO concentration range of 25 to 50 µg/mL
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was most strongly inhibited. In the case of a liquid phase, B and C transferases were inhibited to
the greatest extent in the presence of LPO in a concentration range of 10 to 100 µg/mL [142]. It has
been hypothesized that this phenomenon is associated with the attachment of LPO (in a sufficiently
high concentration) to Gtfs, changing their conformations and consequently reducing their activity.
A similar inhibitory effect on the enzyme itself without added substrates was previously noted by
Yu et al. investigating the effect of LPO on GtfD derived from S. mutans, while the complete system
strengthened GtfD activity [168]. Liu et al. observed that the addition of iodides to the LPO system
limits adhesion as well as glucosyltransferase-associated EPS synthesis more efficiently than the LPO
system with SCN− alone. This effect increases with the increase of I− concentration [166]. The effect
on S. mutans adhesion was also described by Roger et al. where the LPO used at a concentration range
of 20 to 100 µg/mL reduced the bacterial adhesion to hydroxyapatite proportionally with enzyme
concentration [140]. The LPO system effectively limits the growth of C. albicans fungi in addition to S.
mutans. Welk et al. used a quantitative suspension test for S. mutans, S. sanguinis, and C. albicans in the
presence of the LPO system, and demonstrated a complete killing of S. mutans cells after 5 min (RF 7.49)
and C. albicans cells after 3 min (RF 6.78). The complete killing of S. sanguinis cells occurred after 15 min
(RF 8.12) [167], which could be related to the presence of NADH: hypothiocyanite oxidoreductase in
these cells protected them against OSCN− [133].
The combination of lactoferrin, lysozyme, and LPO present in the toothpastes, effectively increases
the permeability of S. mutans membrane (at a concentration of 5.2 µg/mL paste proteins), inhibits
planktonic growth (at toothpaste protein concentration of 1.4 mg/mL) and reduces the viability of a
single-species biofilm of this pathogen [141]. Such a combination of antibacterial proteins also worked
well in the studies of Pinherio et al., who applied the concentration of 10 µg/mL of each protein and,
after three applications, described a significant S. mutans reduction on the surface of artificially formed
carious lesions on extracted teeth [172].
These studies show that the anti-caries effect of the LPO system tested in vitro, including the
reduction of adhesion, biofilm viability, and inhibition of S. mutans growth, is reflected in the results
of in vivo studies. Oral care products used in them, work together with LPO thanks to the addition
of active proteins such as lactoferrin and lysozyme, intensifying their action especially during teeth
brushing, when the content of active ingredients in the oral cavity is the highest.
8.1.2. Periodontal Disease
Regular and effective removal of dental plaque accumulating in the subgingival zone is an
important element of prevention of gum and periodontal diseases. Such accumulation results in the
development of the inflammatory response of the host with the progressive destruction of the tissues
surrounding the tooth [139]. Numerous studies in the literature described anaerobic bacteria associated
with these diseases, e.g., P. gingivalis [177,178], A. actinomycetemcomitans [179,180], F. nucleatum [181],
and T. denticola [182].
The results of the studies presented in Table 2 demonstrate that the use of lozenges containing LPO,
LF, and GOx gave inconclusive results in terms of the effect on bacteria associated with periodontitis.
Shimizu et al. described that the effect on total bacterial count and P. gingivalis number (in saliva
and supragingival plaque) of people with chronic periodontitis was not significantly different from
the control after 12 weeks of tablet (LPO 1.8 mg/tab) administration three times a day [4]. Morita
et al. observed the reduction in the number of P. gingivalis and F. nucleatum colonizing the tongue
as well as the restriction of tongue coating in the control and test group after eight weeks of tablet
usage (LPO 2.6 mg/tab) [163]. These results may be related not necessarily to the antibacterial effect of
LPO together with LF, but with the mechanical removal of the coating during tablet suction. Tablets,
although having a system ensuring H2O2 generation (i.e., Gox + glucose) and a very high LPO
concentration, did not provide SCN− ions unlike the pastes, hence saliva was their sole source.
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Table 2. Summary of clinical trials and in vitro tests using lactoperoxidase.
Clinical Trials
Preparation Test Group Tested Parameter Effect References
Biotène® Dry Mouth
Moisturizing Spray
(lysozyme, lactoferrin, LPO)
During the recruitment of
people suffering from dry
mouth syndrome
Time after which the participant
will have a dry mouth feeling The study is ongoing
Clinicaltrials.gov
NCT03663231
ZendiumTM
(amyloglucosidase, GOx, LPO)
229 healthy subjects
Mean age = 32.6 years
Modified Gingival
Index (MGI)
Bleeding Index (BI)
Plaque Index
Significant reduction vs. MGI (1.627 vs. 1.404)
and PI (2.233 vs. 2.112) baseline levels in test
group; significant reduction of all parameters
compared to the control group
Daly et al. 2019
[164]
ZendiumTM
(amyloglucosidase, GOx, LPO,
LYS, LF)
46 healthy subjects
Mean age = 42 years
H2O2 and lysozyme levels after
brushing
64% higher H2O2 and 92% higher lysozyme
concentrations vs. concentrations after brushing
with a control paste
Cawley et al. 2019
[141]
ZendiumTM
(amyloglucosidase, GOx, LPO)
115 healthy subjects
Mean age = 42 years
Composition of supra-gingival
dental plaque expressed as a mean
relative abundance (MRA)
In test group: significant changes in MRA of 37
taxa; the highest MRA increase in Neisseria flava
(2.9%), K. denitrificans (0.7%), P. melaninogenica
(0.4%); the lowest MRA decrease in R.
dentocariosa (3.2%), Bacteroidales (0.2%),
Treponema spp (0.08%)
Adams et al. 2017
[183]
ZendiumTM
(amyloglucosidase, GOx, LPO)
68 patients
Age 83.7 ± 7.4 years
Composition of oral microflora
collected from supra-gingival and
lingual area, the presence of visible
supra-gingival plaque (SP)
Significant plaque score reduction after 12
months in test group vs. baseline level (1.7 ± 0.5
vs. 0.7 ± 0.5) and vs. control (1.6 ± 0.4 vs. 1.6 ±
0.6); lack or thin layer of plaque after 12 months
in 92% of test group; F. nucleatum count and
ration significantly decreased in test group;
significant decreased of S. sanguinis/oralis count
during 12 months
Wikström et al. 2017
[162]
OrabarrierTM
(lactoferrin, LPO, GOx)
47 healthy subjects
Mean age
(test group) = 80.4 ± 6.4 years
(control group) =
85.9 ± 6.7 years
Plaque control record (PCR),
probing, pocket depth (PPD),
bleeding on probing (BOP), tongue
coating score, volatile sulfur
compounds (VSCs), H2S, CH3SH,
mouth dryness, Composition of
oral microflora collected from
supra-gingival and lingual area
Significant PPD (after 8 weeks) and BOP (after 8
weeks in test group and after 4 weeks in controls)
decrease in both groups, tongue coating score
decrease after 4 and 8 weeks in both groups;
decrease in P. gingivalis and F. nucleatum count
after 8 weeks in test group
Morita et al. 2017
[163]
Int. J. Mol. Sci. 2019, 20, 1443 13 of 31
Table 2. Cont.
Clinical Trials
Preparation Test Group Tested Parameter Effect References
OrabarrierTM
(lactoferrin, LPO, GOx)
40 participants with VSCs
exceeding the olfactory
threshold in the expired air
Age 49.4 ± 15.3 years
Volatile sulfur compounds (VSCs),
H2S, CH3SH in exhaled air 10 and
30 min after tablet administration
VSCs and H2S decrease (57% and 45%,
respectively); no significant changes of CH3SH
concentration between groups after 10 and
30 min; significantly lower VSCs (0.115 ± 0.078)
and H2S (−0.085 ± 0.083) concentrations in test
group after 10 min vs. controls
Nakano et al. 2016
[159]
Bioxtra®
(GOx, LPO, lactoferrin)
30 children with severe early
childhood caries
Age 3–5 years
Salivary S. mutans i L. acidophilus
count (CFU) before, right after and
after 7 days of toothpaste usage
Significant decrease in CFU of S. mutans
(112.0 ± 13.3 vs. 8.50 ± 5.89) and L. acidophilus
(109.6 ± 14.3 vs. 8.60 ± 3.98) in an enzymatic
paste group during 7 days; significant decrease
of S. mutans count in fluoride (123.1 ± 21.1 vs.
33.6 ± 10.3) and nonfluoride (110 ± 12.4 vs.
76.2 ± 19.6) paste groups
Gudipaneni et al. 2014
[3]
Biotene OralBalance® gel
(LPO, lysozyme lactoferrin)
41 mechanically ventilated
newborns
Age 7–10 days
Respiratory outcomes,
non-respiratory short-term
outcomes, time of ventilation,
composition tracheal
aspirate samples
No significant differences in the duration of
mechanical ventilation; significantly longer
hospitalization of newborns in the study group;
no significant differences in the composition of
the tracheal bacterial flora
Stefanescu et al. 2013
[165]
OrabarrierTM
Tablets
(lactoferrin, LPO, GOx)
74 subjects with chronic
periodontitis
Age 32–73 years
Effect on human and bovine LF
level, P. gingivalis count, exotoxin
level, total bacterial count in saliva
and gingival fluid, plaque control
record (PCR), probing, depth (PD),
bleeding on probing (BOP), plaque
index (PI), gingival index (GI), CAL
(clinical attachment level)
Significantly higher bLF concentration in saliva
and CGF in study group vs. controls;
non-significant effect on bacterial parameters; no
significant differences in periodontal health
parameters vs. control group
Shimizu et al. 2011
[4]
OrabarrierTM
(lactoferrin, LPO, GOx)
15 participants with VSCs
exceeding the olfactory
threshold in the expired air
Volatile sulfur compounds (VSCs),
CH3SH in exhaled air 10 min, 1 h
and 2 h after tablet administration,
bacterial count in saliva
No significant differences in salivary bacterial
count; significantly lower CH3SH concentration
in test group vs. controls
Shin et al. 2011
[160]
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Table 2. Cont.
Clinical Trials
Preparation Test Group Tested Parameter Effect References
BioXtra®
(GOx, LPO, lactoferrin)
34 patients with
radiotherapy-induced
xerostomia
Age 63.5 ± 9.4 years
Intensity of xerostomia symptoms,
effect on dysphagia, pain in oral
cavity, loss of taste (0–3 scale)
Remission of symptoms severity, a significant
reduction in dry mouth feeling (2.03 vs. 1.12),
dysphagia improvement (1.62 vs. 0.76) after
28 days
Dirix et al. 2007
[161]
Biotene®
(GOx, LPO)
12 healthy subjects SCN
−, HOSCN/OSCN right after
brushing
Increase in salivary HOSCN/OSCN-Level and
its decomposition after 20 min
Lenander-Lumikari et
al. 1993
[176]
Biotene®
(GOx, LPO)
26 healthy subjects
SCN−, HOSCN/OSCN, total
bacterial count in saliva,
streptococcal count, S. mutans,
Lactobacillus spp
No significant inhibitory effect on the growth of
the tested species
Lenander-Lumikari et
al. 1993
[176]
In vitro studies
Tested substance Microorganism Tested parameter Effect References
Amyloglucosidase, GOx, LPO,
LF, LYS and bovine colostrum
(IgG)
S. mutans,
Fusobacterium nucleatum
Film integrity and polarity using
fluorescent dyes
Significant increase in fluorescence connected to
a film polarity (33.3% for S. mutans) and
permeability (44.4% increase for S. mutans and
57.6% increase for F. nucleatum)
Cawley et al. 2019
[141]
Amyloglucosidase, GOx, LPO,
LF, LYS and bovine colostrum
(IgG)
S. mutans
Fusobacterium nucleatum
Effect of toothpaste on planktonic
growth
Significant reduction in the growth of both
strains
Cawley et al. 2019
[141]
ZendiumTM
S. mutans
Fusobacterium nucleatum
Effect of toothpaste on the viability
of a single-species biofilm
Significant reduction in S. mutans biofilm
viability (40% decrease in fluorescence);
insignificant reduction of F. nucleatum biofilm
viability (23% decrease in fluorescence) vs.
control paste
Cawley et al. 2019
[141]
ZendiumTM
S. mitis
S. intermedius
S. oralis
Actinomyces naeslundii
Veillonella dispar
Fusobacterium nucleatum
Prevotella intermedia
Effect of toothpaste on the viability
of a seven-species biofilm
30% decrease of viability after 2 h; 27% decrease
of viability after 4 h; 47% decrease of viability
after 8h vs. control paste
Cawley et al. 2019
[141]
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Table 2. Cont.
Clinical Trials
Preparation Test Group Tested Parameter Effect References
Splat Oral Care Foam (LF, GOx,
LPO)
Staphylococcus aureus
Kocuria rhizophila
Micrococcus thailandicus, E. coli
Chromobacterium violaceum
bacteria from pooled saliva
Retention test of growing and
mature biofilms made on glass,
Teflon and tooth surface after 5 and
30 s of rinsing with foam
Reduction of biofilm retention on glass and
Teflon after foam rinsing for 30 s (all species
except C. violaceum; 86.9% retention on Teflon);
significant reduction of biofilm retention from
pooled saliva on enamel
Jones et al. 2018
[171]
MPO, CAT, LPO, HRP
S. sanguinis, S. cristatus, S.
gordonii, S. parasanguinis, S.
mitis, S. salivarius, S. oralis, A.
viscosus, S. mutans, Actinomyces
naeslundii, Veilonella parvula, S.
sorbinus, Prevotella intermedia,
Porphyromonas gingivalis,
Fusobacterium nucleatum,
Aggregatibacter,
actinomycetemcomitans
Evaluation of multispecies ecology
in terms of the inhibitory effect of
peroxidases at the concentration of
those in saliva, gingival fluid
present in PD and gums, on the
inhibitory effects of commensal
bacteria on pathogenic strains
MPO, CAT, and HRP reduce the inhibitory effect
of commensal biofilms in concentrations
occurring in the gingival fluid in patients with
periodontitis and gingivitis; higher P. gingivalis
and P. intermedia overgrowth in a multispecies
biofilm compared to the increase of CF
myeloperoxidase in healthy subjects; the
presence of LPO and MPO in salivary
concentrations found in people with
periodontitis resulted in P. gingivalis and P.
intermedia overgrowth; LPO had an inhibitory
effect on planktonic growth of A. naeslundii,
A. viscosus and growth of S. sobrinus and S. oralis
in biofilms
Herrero et al. 2018
[170]
(1) LPO, LF, LYS (LLL);
(2) casein
phosphopeptide-amorphous
calcium phosphate (CPP-ACP)
S. mutans Bacterial count in induced cariouslesions on human teeth
Significant reduction of S. mutans count after
3-fold LLL administration; CPP-ACP does not
reduce S. mutans count
Pinherio et al. 2017
[172]
LPO system, iodide S. mutans
Measurement of the effect on
growth, glucosyltransferase activity,
adhesion and synthesis of
exopolysaccharides (EPS)
The inhibitory effect of the system increases with
I− concentration; reduction of
glucosyltransferase activity and EPS synthesis
Liu et al. 2014
[166]
2 artificial salivae containing (1)
GOx, LF, LYS, LPO
(2) carboxymethylcellulose
Candida albicans
Comparison of the degree of
inhibition of C. albicans growth on
acrylic plates
Saliva containing enzymes did not show a
statistically significant reduction in the amount
of microorganisms vs. saliva with
carboxymethylcellulose
Silva et al. 2012
[173]
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Table 2. Cont.
Clinical Trials
Preparation Test Group Tested Parameter Effect References
LPO system
S. mutans
S. sanguinis
C. albicans
Quantitative suspension test and
calculation of reduction factor (RF)
after 1, 3, 5 and 15 min
Suspensions treated with only SCN/H2O2
mixtures did not show antibacterial or
antifungal activity; LPO addition significantly
increased RF of all microorganisms
Welk et al. 2009
[167]
LPO system S. mutans glucosyltransferases B,C, and D
Glucosyltransferases activity in the
liquid phase and adsorbed on
hydroxyapatites
Significant inhibition of GtfC and GtfD adsorbed
by the system; no effect on GtfC activity and an
increase in GtfB activity in the liquid phase
Korpela et al. 2002
[142]
LPO system S. mutans glucosyltransferase D Glucosyltransferase activity
GtfD activity increased by the system; no
influence of OSCN− on GtfD activity; LPO
inhibits GtfD activity in low concentrations
Yu et al. 2000
[168]
Immune whey
LPO system S. mutans serotype c Inhibition of glucose retention
Exposure to HOSCN/OSCN− as a product of
LPO action enhances the inhibition by the
immune whey glucose retention
Loimaranta et al. 1998
[174]
LPO
LYS S. mutans serotype c
Capacity of a strain to adhere to
hydroxyapatite previously treated
with saliva after administration of
specific concentrations of the
substance
Significant reduction in adhesion Roger et al. 1994[140]
LPO system Bacillus cereus Growth curves Inhibition of bacterial growth proportional to theconcentration of the produced OSCN− ion
Tenovuo et al. 1985
[169]
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Enzymatic toothpastes are frequently used in clinical trials in addition to tablets. Daly et al.
observed that the use of enzymatic paste in healthy subjects for 13 weeks significantly affected
such parameters of gingival health, as modified gingival index, bleeding index, and plaque index,
as compared to the control group using fluoride-only paste [164]. The same paste showed efficacy
in increasing the permeability of the cell membrane (in the presence of 7.8 µg/mL paste proteins)
and inhibiting the planktonic growth of F. nucleatum (in the presence of 1.4 mg/mL paste proteins).
Tenovuo et al. showed that B. cereus, i.e., another periodontopathic species, shows suppression of
planktonic growth in the presence of the LPO system (in 2 µg/mL concentration). This effect escalated
with the amount of generated OSCN−, reaching 100% for 169 µM of this product. Paste dilutions used
by Cawley et al. were similar to that occurring in oral cavity during brushing and showed a reduction
in the viability of a seven-species biofilm composed of commensal and pathogenic bacteria associated
with periodontal disease (Table 2). Wikström et al. examineda reduction in visible plaque score, which
was obtained in the study group within 12 months of a weekly professional tooth cleaning with LPO
paste. Viable microbial count of F. nucleatum in the tongue coating and supragingival plaque was lower
than in the control group. The proportion of Lactobacilli in the dental plaque in both groups during
the experiment, however, gradually increased in supragingival plaque while there were no significant
differences in the microbial count of S. mutans, Lactobacillus spp., and Actinomyces between the control
and test groups [162]. This could be due to the simultaneous intake of several drugs by the participants
and the associated reduction in salivary flow rate (<4.0 µL/cm/min in 76% of participants), which
resulted in decreased buffering capacity of the organic acids produced by acidogenic bacteria, creating
a favorable environment for their growth.
It appears that the composition of the preparation ensuring adequate access of substrates for
lactoperoxidase is an important factor in the products used for oral hygiene. Tooth brushing allows
one to remove dental plaque and assure an access of active proteins to the deeper layers of biofilm.
This provides a noticeable reduction of visible plaque as well as improved gum health.
8.1.3. Other Applications
The study conducted by Nakano et al. with the use of the tablets with LPO (2.6 mg/tab) and LF
in patients with malodor report a significant reduction in the level of VSCs and H2S within 10 min
after a single administration compared to control [159]. After the same time after administration of
a tablet containing 1.8 mg of LPO per tablet, Shin et al. observed a decrease in CH3SH and VSCs
compared to the control [160]. This positive effect on the reduction of malodor can be associated
with the mechanical removal of the tongue coating (which has a significant impact on the level of
VSCs [184,185]) on the one hand, and with the possible OSCN−/HOSCN activity produced by LPO,
on the other. These products react with the cysteine residues of the methionine γ-lyase enzyme present
in anaerobic periodontopathic bacteria (e.g., F. nucleatum and P. gingivalis) and inhibit its activity and
the formation of VSCs responsible for bad breath [186].
Xerostomia is another oral disease, where LPO-containing products are used. The protective effect
of saliva in patients struggling with this problem is limited, which results in their greater susceptibility
to the development of caries [187]. There are numerous products in the form of gels and rinses
that contain natural defensive proteins, including LPO, LYS, LF, and immunoglobulins [188]. These
products effectively relieve symptoms such as swallowing problems, dry mouth, loss of taste [161].
Guneri et al. showed in vitro inhibitory effect for only some moisturizing products on the growth of
S. mutans and L. acidophilus and no inhibition of C. albicans growth. Nevertheless, due to the lack of
data on the exact composition of the products, the question what could cause these discrepancies was
not resolved [188]. Silva et al. did not observe any inhibitory effect artificial saliva containing LPO,
LF, and LYS on the formation of C. albicans biofilm on acrylic plaques in contrast to saliva containing
carboxymethylcellulose (CMC) [173]. A 2-week clinical trial in patients suffering from xerostomia
after irradiation didn’t show any significant differences in the amount of S. mutans, L. acidophilus, and
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C. albicans present in the saliva between the therapy using products containing LPO, LYS, and LF,
or the one containing CMC [189].
Stefanescu et al. carried out pilot studies to pre-determine whether a regular application of an
oral hygiene gel containing LPO, LYS, and LF would allow the prevention of VAP in mechanically
ventilated infants. The tracheal flora samples collected during the study showed no differences in
composition, density, or changes of density compared to the control group. There were no differences
in the time of hospitalization or the time remaining under mechanical ventilation. It was suggested
that the results could have been influenced by the late intervention onset (after the 7th day of life),
endotracheal tube, and a previous use of antibiotics in some infants [165].
8.2. Dentifrices with the LPO System
Available dentifrices containing the LPO system usually consist of lactoperoxidase, potassium
thiocyanate, and a system for generating hydrogen peroxide such as glucose oxidase (GOx), xanthine
oxidase (XO), or lactose oxidase. In addition, these preparations are often enriched with other
nonspecific bioactive components such as lactoferrin, lysozyme, or antigen-specific immunoglobulins
of bovine milk.
Lactoferrin is a glycoprotein belonging to the transferrin family that has the ability to bind iron.
Its antibacterial properties are due to the ability of iron sequestration which makes it inaccessible
to many species of bacteria, including cariogenic S. mutans [190]. In addition, it interacts with
Gram-negative lipopolysaccharide, releasing it into the environment [191].
Lysozyme (EC.3.2.1.17), or muramidase, is a strongly cationic antibacterial protein found in many
body fluids [192]. Its activity is based on the hydrolysis of glycosidic bonds in peptidoglycan of
bacterial cell walls [193,194] and increase in cell membrane permeability, as well as inhibiting biofilm
formation [195].
The combination of naturally occurring proteins found in oral hygiene products enhances their
mutual effects and supports the antimicrobial protection system of the host, resulting in improved
gingival health parameters and changes in ecology of the bacterial flora, i.e., the increase of the share
of species related to oral health [183]. Protein components of the pastes may be deposited on the
surface of the renewing pellicle after brushing. In the case of LPO, its activity was detectable after
40 min from the formation of the acquired pellicle for three tested enzymatic pastes [196]. Despite
the market availability of many other forms of application of oral hygiene products containing LPO
(such as lozenges, gels, foams, and mouthwashes), it is important to remember that they constitute a
supplement to teeth brushing and can be easily omitted during an everyday oral care routine, while
providing a convenient alternative to a toothpaste for use outside the home [171].
Currently, caries prophylaxis involves the use of classic fluoride preparations [187,197,198]
and intensively studied nonfluoride methods including chlorhexidine [199], probiotics [200],
xylitol [199,201], triclosan [202], CPP-ACP [203], and proteins of natural origin. Dentifrices with the
addition of antibacterial proteins such as LPO may be an alternative to common fluoride preparations.
The currently recommended form of caries prophylaxis involves the use of pastes and other
products containing fluoride [204]. Despite the wide prevalence of this prophylaxis, caries and
periodontal disease are still a major problem in every age group. The use of varnishes and gels with a
high content of F− and low pH (3.5–5) may cause local inhibition of OSCN− production through the
LPO system, whereas fluoride present in enzymatic pastes does not show any inhibitory effect on the
LPO system because it ensures pH > 5.5 [205].
A mild surfactant, stearyl ethoxylate 30, is used in pastes with the LPO system instead of the
commonly used sodium lauryl sulfate (SDS). SLS has been shown to cause reduction of the protective
effect of mucin of the mucous membrane, desquamation of oral epithelium, and contributes to the
development of irritation [206,207] and gingival sloughing [206].
Chlorhexidine (CHX) used in rinses and gels as one of the ways to reduce plaque in gingivitis,
is characterized by a strong bactericidal effect due to its positive charge allowing adsorption on
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the mucous surface, teeth, biofilm components including bacteria, EPS, and glycoproteins [208].
The long-term use of this agent is, however, associated with the occurrence of discoloration of
teeth [209,210], tongue and mucous membrane [208], taste loss [211], epithelial desquamation, and
calculus formation [212]. In contrast to chlorhexidine, the products of the LPO system have a selective
effect (does not show biocidal effects on certain species of microbes of physiological flora) and do not
damage the cells of the host [133]. The effect of discoloration was also described after using a rinse
containing stannous fluoride (SnF2) and essential oils [213]. CPP-ACP is used in the remineralization
of enamel but has no antibacterial activity compared to LPO [172]. On the other hand, the habitual
consumption of xylitol showing bacteriostatic and antibiofilm activity [214], may lead to the growth of
xylitol-resistant S. mutans strains in the plaque and loss of its effectiveness [215]. So far, no side effects
have been demonstrated due to the long-term use of preparations containing lactoperoxidase.
9. Stability Extension
Due to the widespread use of lactoperoxidase in the cosmetic, pharmaceutical, and food industries,
it is required to increase its stability in finished products and ensure a long period of its activity
maintenance. The choice of stabilizing substances is very important in creation of oral care preparations
containing active enzymes in an aqueous environment, so that they do not degrade during a long-term
storage at a room temperature. Nimatullah et al. showed that LPO stored in the aqueous environment
quickly loses its activity. They demonstrated a total loss of its activity at 25 ◦C during the first week,
while at 4 ◦C the sample lost half its initial activity during the third week of the experiment. The best
effects have been proven in the case of −20 ◦C freezing, as there was no activity decrease throughout
the duration of the 4-week experiment [216]. As it is practical for oral hygiene preparations to be stable
at room temperature, methods to ensure this are still being sought.
Lyophilization (freeze-drying) is one of the most effective processes for prolonging the stability of
biologically active compounds. In addition, lyophilized substances take up considerably less space
during storage than solutions [217]. Shariat et al. showed that the use of lyophilization with trehalose
as a lyoprotectant allowed LPO to be fully active for 41 days (duration of the experiment), while the
freeze-dried enzyme without the addition of trehalose lost its activity below 5% after 2 days [218].
This method of stability extension is well suited for preparations for use in the laboratory or industry,
but is not suitable for oral care preparations for practical reasons.
Osmolytes are substances that protect proteins against loss of their function due to the action of
temperature, urea or salt [219]. Boroujeni et al. also examined the possibility of using osmolyte ectoine
as a stabilizing agent for the changes in pH and temperature [220]. The enzyme remained the most
active at 25 ◦C and pH of 6.4 in the presence of ectoine. The change in pH resulted in a decrease in
LPO activity; however, it did not decrease below approximately 50% of the initial value. With the pH
maintained at the 6.4 level, and the temperature increased from 25 to 70 ◦C, the addition of ectoine
allowed for the maintaining of over 80% LPO activity [220]. In the context of oral care preparations,
the use of ectoine as an LPO stabilizer is safe due to the lack of toxicity of this compound [221] and the
assurance of stabilization in a water environment such as toothpaste.
Immobilization on solid particles as polymers or nanoparticles is more and more widely used
technique of enzyme stabilization. Jafar et al. demonstrated that the immobilization of LPO on
polyaniline molecules allowed full enzyme activity at 4 ◦C for 60 days, while the native LPO sample
lost 80% of its original activity. In addition, immobilized LPO showed a greater stability to the pH of
the environment and was more difficult to denature at 60 ◦C [222].
Application of Nanotechnology
Nanoparticles are characterized by a high surface to volume ratio, therefore different physical
and chemical properties than the macroforms of the same compound/element [223]. Due to their
properties, they are used as drug carriers allowing easier penetration into the cells, increasing the
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durability of the drug and controlling its release; moreover, showing a therapeutic effect in some
cases [224].
Altinkaynak et al. combined hybrid copper nanoflowers with LPO which contributed to the
extension of the preparation’s durability. Researchers showed that only 5% of the initial LPO activity
was lost at 20 ◦C after 15 days using this combination, as compared to 95% loss of activity of the
native LPO preparation under the same conditions. In most cases, the adsorption of enzymes on
nanoparticles contributed to a decrease in their specific activity, however, in this case the combination
of lactoperoxidase with hybrid copper nanoflowers increased this enzymatic parameter [225]. A similar
increase in enzyme activity using silver nanoparticle conjugates (AgNPs) was obtained by Sheikh et
al. [226]. Such immobilization of LPO probably allowed for increasing the stability of the enzyme
with an additional increase in the surface where SCN− ions could be oxidized. This resulted in an
evident inhibition of E. coli growth just after 2 h. AgNPs have also demonstrated stabilizing properties
on the enzyme, because the bactericidal action of LPO in combination with AgNPs was maintained
throughout the duration of the experiment, in contrast to the native enzyme preparation with a loss in
this property after 6 h [226]. In addition, AgNPs themselves have antimicrobial properties, further
enhancing the biocidal effect of the conjugate [227], which has been used in the prevention of caries by
creating toothpastes containing AgNPs [228].
Another example of nanoparticles use with LPO is described by Shariat et al. who performed
immobilization on graphene oxide nanosheets (GO-NS) [229]. It resulted in increased LPO activity
at a more basic pH compared to the enzyme itself, but was also maintained at high activity at 70 ◦C.
Additionally, the immobilized LPO maintained activity at the level of 64% of the initial value after
30 days of storage [229].
These examples demonstrate the additional advantages of using particular stabilizers for LPO,
especially in terms of potential use in oral preparations that must be stable when stored for a long time
at a room temperature. Moreover, the use of nanomaterials may have additional benefits in the form
of their own biocidal activity against microorganisms responsible for oral infectious diseases.
There are still few studies on the use of nanomaterials to stabilize LPO, moreover, the exact
mechanism of this stabilization and the increase in specific enzyme activity observed by some
teams of researchers [225,226] is unknown. One of the proposed theories of protein stabilization
by nanoparticles is the steric repulsion between proteins deposited on nanoparticles, which prevents
their aggregation [230]. Determination of the toxicological safety of nanomaterials in relation to
humans and the environment is another clinically important aspect [231].
10. Summary
In recent years, intensive research has been carried out on nonfluoride methods of caries
prevention as well as new methods of alleviating the symptoms of periodontitis. Compounds of
natural origin such as lactoperoxidase are of particular interest. This paper presents the results of
a series of studies proving the effectiveness of the lactoperoxidase system in the prevention and
alleviation of the symptoms of particular oral diseases. It seems that the next step in the research on
the LPO potential will be aimed at finding other reactivators of this enzyme as well as determining
their effectiveness in microbiological systems and then assessing their usefulness in clinical trials.
The promising field of research comprises the use of nanotechnology in the creation of new carriers of
lactoperoxidase that would favorably affect its properties.
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thiocyanate as a biomarker of tobacco smoke constituents in selected biological materials of human origin.
Biomed. Chromatogr. 2018, 32, e4111. [CrossRef] [PubMed]
92. Schultz, C.P.; Ahmed, M.K.; Dawes, C.; Mantsch, H.H. Thiocyanate levels in human saliva: Quantitation by
Fourier transform infrared spectroscopy. Anal. Biochem. 1996, 240, 7–12. [CrossRef]
93. Paul, B.D.; Smith, M.L. Cyanide and thiocyanate in human saliva by gas chromatography-mass spectrometry.
J. Anal. Toxicol. 2006, 30, 511–515. [CrossRef]
94. Chen, Z.-F.; Darvell, B.W.; Leung, V.W.-H. Human salivary anionic analysis using ion chromatography.
Arch. Oral Biol. 2004, 49, 863–869. [CrossRef]
95. Felker, P.; Bunch, R.; Leung, A.M. Concentrations of thiocyanate and goitrin in human plasma, their precursor
concentrations in brassica vegetables, and associated potential risk for hypothyroidism. Nutr. Rev. 2016, 74,
248–258. [CrossRef] [PubMed]
96. Conner, G.E.; Wijkstrom-Frei, C.; Randell, S.H.; Fernandez, V.E.; Salathe, M. The lactoperoxidase system
links anion transport to host defense in cystic fibrosis. FEBS Lett. 2007, 581, 271–278. [CrossRef]
97. Fragoso, M.A.; Fernandez, V.; Forteza, R.; Randell, S.H.; Salathe, M.; Conner, G.E. Transcellular thiocyanate
transport by human airway epithelia: Transcellular thiocyanate transport by human airway epithelia.
J. Physiol. 2004, 561, 183–194. [CrossRef]
98. Peters, C.J.; Yu, H.; Tien, J.; Jan, Y.N.; Li, M.; Jan, L.Y. Four basic residues critical for the ion selectivity and
pore blocker sensitivity of TMEM16A calcium-activated chloride channels. Proc. Natl. Acad. Sci. USA 2015,
112, 3547–3552. [CrossRef]
99. Pedemonte, N.; Caci, E.; Sondo, E.; Caputo, A.; Rhoden, K.; Pfeffer, U.; Di Candia, M.; Bandettini, R.;
Ravazzolo, R.; Zegarra-Moran, O.; et al. Thiocyanate transport in resting and IL-4-stimulated human
bronchial epithelial cells: Role of pendrin and anion channels. J. Immunol. 2007, 178, 5144–5153. [CrossRef]
100. Rosin, M.; Kramer, A.; Bradtke, D.; Richter, G.; Kocher, T. The effect of a SCN-/H2O2 toothpaste compared
to a commercially available triclosan-containing toothpaste on oral hygiene and gingival health - a 6-month
home-use study. J. Clin. Periodontol. 2002, 29, 1086–1091. [CrossRef]
101. Kirstilä, V.; Lenander-Lumikari, M.; Tenovuo, J. Effects of a lactoperoxidase-system-containing toothpaste on
dental plaque and whole saliva in vivo. Acta Odontol. Scand. 1994, 52, 346–353. [CrossRef]
102. Furtmüller, P.G.; Burner, U.; Jantschko, W.; Regelsberger, G.; Obinger, C. Two-electron reduction and
one-electron oxidation of organic hydroperoxides by human myeloperoxidase. FEBS Lett. 2000, 484, 139–143.
[CrossRef]
103. Furtmüller, P.G.; Burner, U.; Obinger, C. Reaction of Myeloperoxidase Compound I with Chloride, Bromide,
Iodide, and Thiocyanate. Biochemistry 1998, 37, 17923–17930. [CrossRef]
104. Furtmüller, P.G.; Jantschko, W.; Regelsberger, G.; Jakopitsch, C.; Arnhold, J.; Obinger, C. Reaction of
Lactoperoxidase Compound I with Halides and Thiocyanate †. Biochemistry 2002, 41, 11895–11900. [CrossRef]
105. Harden, R.M.; Alexander, W.D.; Shimmins, J.; Chisholm, D. A comparison between the gastric and salivary
concentration of iodide, pertechnetate, and bromide in man. Gut 1969, 10, 928–930. [CrossRef]
106. Rodríguez-López, J.N.; Gilabert, M.A.; Tudela, J.; Thorneley, R.N.F.; García-Cánovas, F. Reactivity of
Horseradish Peroxidase Compound II toward Substrates: Kinetic Evidence for a Two-Step Mechanism
†. Biochemistry 2000, 39, 13201–13209. [CrossRef]
107. Che, H.; Tian, B.; Bai, L.; Cheng, L.; Liu, L.; Zhang, X.; Jiang, Z.; Xu, X. Development of a test strip for rapid
detection of lactoperoxidase in raw milk. J. Zhejiang Univ. Sci. B 2015, 16, 672–679. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 1443 26 of 31
108. Bach, C.E.; Warnock, D.D.; Van Horn, D.J.; Weintraub, M.N.; Sinsabaugh, R.L.; Allison, S.D.; German, D.P.
Measuring phenol oxidase and peroxidase activities with pyrogallol, l-DOPA, and ABTS: Effect of assay
conditions and soil type. Soil Biol. Biochem. 2013, 67, 183–191. [CrossRef]
109. Huwiler, M.; Jenzer, H.; Kohler, H. The role of compound III in reversible and irreversible inactivation of
lactoperoxidase. Eur. J. Biochem. 1986, 158, 609–614. [CrossRef]
110. George, P. The third intermediate compound of horseradish peroxidase and hydrogen peroxide. J. Biol. Chem.
1953, 201, 427–434.
111. Gau, J.; Furtmüller, P.G.; Obinger, C.; Prévost, M.; Van Antwerpen, P.; Arnhold, J.; Flemmig, J. Flavonoids as
promoters of the (pseudo-)halogenating activity of lactoperoxidase and myeloperoxidase. Free Radic. Biol.
Med. 2016, 97, 307–319. [CrossRef]
112. Gau, J.; Furtmüller, P.-G.; Obinger, C.; Arnhold, J.; Flemmig, J. Enhancing hypothiocyanite production by
lactoperoxidase – mechanism and chemical properties of promotors. Biochem. Biophys. Rep. 2015, 4, 257–267.
[CrossRef]
113. Flemmig, J.; Rusch, D.; Czerwińska, M.E.; Rauwald, H.-W.; Arnhold, J. Components of a standardised olive
leaf dry extract (Ph. Eur.) promote hypothiocyanite production by lactoperoxidase. Arch. Biochem. Biophys.
2014, 549, 17–25. [CrossRef]
114. Flemmig, J.; Noetzel, I.; Arnhold, J.; Rauwald, H.-W. Leonurus cardiaca L. herb extracts and their constituents
promote lactoperoxidase activity. J. Funct. Foods 2015, 17, 328–339. [CrossRef]
115. Gomes, D.A.S.; Pires, J.R.; Zuza, E.P.; Muscara, M.N.; Herrera, B.S.; Spolidorio, L.C.; Toledo, B.E.C.;
Spolidorio, D.M.P. Myeloperoxidase as inflammatory marker of periodontal disease: Experimental study in
rats. Immunol. Invest. 2009, 38, 117–122. [CrossRef]
116. Alfonso-Prieto, M.; Biarnés, X.; Vidossich, P.; Rovira, C. The molecular mechanism of the catalase reaction.
J. Am. Chem. Soc. 2009, 131, 11751–11761. [CrossRef]
117. Seidel, A.; Parker, H.; Turner, R.; Dickerhof, N.; Khalilova, I.S.; Wilbanks, S.M.; Kettle, A.J.; Jameson, G.N.L.
Uric Acid and Thiocyanate as Competing Substrates of Lactoperoxidase. J. Biol. Chem. 2014, 289, 21937–21949.
[CrossRef]
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silver and gold in toothpastes: A comparative analysis. Stomatologija 2015, 17, 9–12.
229. Shariat, S.Z.A.S.; Borzouee, F.; Mofid, M.R.; Varshosaz, J. Immobilization of lactoperoxidase on graphene
oxide nanosheets with improved activity and stability. Biotechnol. Lett. 2018, 40, 1343–1353. [CrossRef]
230. Brahmkhatri, V.P.; Chandra, K.; Dubey, A.; Atreya, H.S. An ultrastable conjugate of silver nanoparticles and
protein formed through weak interactions. Nanoscale 2015, 7, 12921–12931. [CrossRef]
231. Bahadar, H.; Maqbool, F.; Niaz, K.; Abdollahi, M. Toxicity of Nanoparticles and an Overview of Current
Experimental Models. Iran. Biomed. J. 2016, 20, 1–11.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
